Aduro Biotech's CRS-207 fails in pancreatic cancer immunotherapy trial

17 May 2016

USA-based Aduro Biotech (Nasdaq: ADRO) lost almost a third of its share price on Monday after missing the primary endpoint in its trial of CRS-207, a treatment that was being evaluated alone, and alongside GVAX Pancreas, for pancreatic cancer.

The Phase IIb ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting.

Median overall survival (MOS) in this third-line and greater setting was 3.8 months for people treated with the immunotherapy regimen of CRS-207 and GVAX Pancreas, 5.4 months for those given CRS-207 alone and 4.6 months for patients administered chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK